TG

Tricares Gmbh

www.tricares.com link_icon

TRiCares Company Research Report



Company Overview


  • Name: TRiCares

  • Mission: To revolutionize healthcare by innovating and being close to patients. TRiCares pioneers in transcatheter minimally invasive technology, aiming to develop a breakthrough tricuspid heart valve replacement system to improve the quality of life for patients. The commitment to excellence drives the creation of safe, effective, and user-friendly products for healthcare professionals.

  • Founded: 2013

  • Founders: Information not provided

  • Key People:

  • Ahmed Elmouelhi, President & CEO

  • Esther Gerteis, VP Medical & Regulatory Affairs

  • Laura Ghione, Chief Operating Officer

  • Headquarters:

  • Paris, France

  • Munich, Germany (office)

  • Number of Employees: Information not provided

  • Revenue: Information not provided

  • Known For: Development of minimally invasive tricuspid valve replacement systems.


Products


Topaz System


  • Description: The Topaz Transfemoral Tricuspid Valve Replacement (TTVR) System is engineered to replace the native tricuspid heart valve using a minimally invasive transfemoral approach, without the need for prior surgical removal of the diseased valve. It's specifically designed for use in the tricuspid position, offering safe, easy implantation to eliminate tricuspid regurgitation (TR).

  • Components:

  • Topaz Heart Valve Prosthesis: A self-expanding biological heart valve constructed from two pre-connected structural components:

  • Outer Stent: Anchors on the native tricuspid leaflets and adapts to various shapes and dimensions of patients' anatomy.

  • Inner Stent: Functions as the skeleton for the three-leaflet pericardial tissue valve, designed for optimal valve function and durability.

  • Topaz Implantation System: Comprises of:

  • Steerable Sheath: Ensures atraumatic access into the transfemoral venous vessel, providing a perpendicular landing onto the tricuspid annulus through active deflection.

  • Delivery System: Features a user-friendly deployment mechanism for the accurate positioning of the Topaz Prosthesis.

  • Key Features:

  • Minimally invasive procedure designed for ease and speed.

  • Utilizes state-of-the-art biological heart valve materials.

  • A unique French/German co-developed design.

  • A two-in-one stent design for effective treatment of tricuspid regurgitation.


Recent Developments


  • New Products: No new products announced.

  • New Features: No specific new features announced.

  • Partnership and Milestones:

  • September 24, 2024: First Topaz Implantation in EU Pivotal Study.

  • July 25, 2024: Raised $50m in Series D Financing for upcoming clinical milestones.

  • March 25, 2024: Ahmed Elmouelhi appointed as President & CEO.

  • December 21, 2023: Successful implantation of Topaz system in a patient with pacemaker.

  • December 6, 2022: Closed Series C Financing, raising €51m for further development and clinical trials.

  • August 30, 2022: First successful implantation of the Topaz system in the TRICURE study.

  • Participation in the Horizon 2020 research and innovation programme under the European Union’s funding.


Contact


  • German Operations: TRiCares GmbH, Heisenbergbogen 2, 85609 Aschheim / Munich, Germany

  • French Headquarters: TRiCares SAS, 27 Avenue de l’Opéra, 75001 Paris, France

  • Email: info@tricares.de